Part of a three volume series.
Over one billion people suffer from fungal infections worldwide, and this number is growing Though Athlete's foot, dandruff, vaginal yeast infection and fungal nail make up the bulk of these cases, there has been a steady increase in the incidence of more serious infections.

This is partially due to the widespread use of antibiotics, which eliminate or decrease fungi-killing bacteria. The increased number of individuals with reduced immune responses caused by AIDS or the effects of chemotherapy has also been a factor. These are part of the factors that have lead to nearly 6-billion dollar antifungal drug industry.

Anti-Infectives, Second Edition, Volume I: Antifungals is a comprehensive review of the market for anti fungal drugs. This is the first volume of Kalorama Information’s 2nd edition of its popular three-part series on anti-infective markets. The report focuses on two segments of antifungal treatment: systemic and topical. The report covers both currently marketed and late stage development antifungal products in detail.

For both the systemic and topical antifungal markets, this report includes:

• U.S. and World Revenues
• Forecasts to 2011.
• Overview and Incidence Data
• Description of Products on the Market
• Review of Products in Development
• Competitive Analysis of Leading Providers.
• 10 Key Issues and Trends facing the antifungal industry

Revenues for each segment were generated using dollar and unit sales for each product. All market data pertain to the world market at the manufacturers’ level. Revenues and market share of major brands such as Lamisil, Diflucan, Sporanox, Cancidas, Vfend, and others are included.

Competitive analysis is provided for the year 2006. The forecasted market analysis for 2004-2011 was based on probability of approval and sales of products in late stage development, product marketing, and demographic trends.

As part of Kalorama's trusted information-gathering process, the information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information and developing forecasts.

For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

Related Reports:

The Worldwide Market for Cancer Diagnostics, 4th Edition
Apr 1, 2010 - KLI2504623 - $4,200.00

The Global Market for Medical Devices
Mar 1, 2010 - KLI2592223 - $1,500.00

The Worldwide Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)
Oct 1, 2009 - KLI2435380 - $3,500.00

2009 Worldwide Diagnostics Market Research Bundle
Oct 1, 2009 - KLI2401913 - $5,995.00

The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets
Oct 1, 2009 - KLI2384194 - $3,995.00

Implant-Based Dental Reconstruction: World Dental Implant and Bone Graft Market, 3rd Edition
Sep 1, 2009 - KLI2284095 - $3,500.00

Infectious Disease Diagnostic Markets
Aug 1, 2009 - KLI2391680 - $3,500.00

Vaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
Jun 1, 2009 - KLI2155319 - $3,995.00

H1N1 (Swine Influenza) Market Assessment (Latest Data, Company Profiles, Implications for Immunoassays and Molecular Assays)
May 1, 2009 - KLI2241990 - $800.00

The World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition
May 1, 2009 - KLI2218043 - $3,995.00